Some of the issues that the Minister is referring to were raised with me by Norgine, a pharmaceutical manufacturer in my constituency with a significant presence and it happens to be a Welsh anchor company, as well. The company made me aware of the consultation that the All Wales Medicines Strategy Group are currently undertaking—I think it closes on Friday—that is looking at conditions for which over-the-counter items should not be routinely prescribed in primary care. It seems to be a cut-and-paste consultation from one that took place earlier in England. The document lists 1,314 medicines available over the counter that are currently prescribed by GPs in Wales, covering 35 conditions. Norgine have raised some concerns with me, particularly the potential unintended consequences of adopting the guidance, including increased costs; disempowering prescribers; putting patients' outcomes at risk; creating inequalities in healthcare; and putting the most vulnerable members of society at risk. Will the Minister reflect on those concerns and also tell the Chamber when he plans to report back to this Parliament on the outcome of that consultation?